Stay updated on Nivolumab and Relatlimab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe revision tag on the page updated from v3.6.4 to v3.6.5. This reflects a new version of the page in the revision history.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA new Revision: v3.6.4 tag has been added. The previous Revision: v3.6.3 tag, along with certain related topics text (Melanoma, MedlinePlus Genetics), was removed.SummaryDifference0.2%

- Check49 days agoChange DetectedMetadata and related topics were updated, and the revision tag was changed from v3.6.2 to v3.6.3. These changes adjust navigation and context without altering the study details.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page’s revision label was updated from v3.6.0 to v3.6.2 to reflect a new build. This update records the updated software version without changing the page’s content or functionality.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded related topic tags for Melanoma and MedlinePlus Genetics. These additions connect the study page with broader melanoma-related and genetics resources, providing quick access to contextual materials.SummaryDifference0.2%

- Check70 days agoChange DetectedThe page now indicates that the study is no longer recruiting participants and adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention / Treatment label was updated to Intervention/Treatment and the site revision is updated to v3.6.0 from v3.5.5.SummaryDifference0.4%

Stay in the know with updates to Nivolumab and Relatlimab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.